Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with breast cancer published in the Journal of the National Comprehensive Cancer Network.

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

The research reveals that dronedarone, previously used for atrial fibrillation, could significantly suppress ESCC cell growth by targeting the CDK4/6-RB1 pathway, a key regulator of the cell cycle ...